General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-05-10 | 2022-03 | -0.12 | N/A | N/A | N/A |
2022-03-28 | 2021-12 | -0.13 | N/A | N/A | N/A |
2021-11-10 | 2021-09 | -0.47 | N/A | N/A | N/A |
2021-08-12 | 2021-06 | -0.8 | N/A | N/A | N/A |
2021-05-13 | 2021-03 | -0.83 | N/A | N/A | N/A |
2021-03-18 | 2020-12 | -0.76 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2021-10-14 | HC Wainwright & Co. | Upgrade | Buy | |
2021-06-03 | Raymond James | Downgrade | Outperform | Market Perform |
2021-06-03 | Baird | Downgrade | Outperform | Neutral |
2021-05-17 | Wells Fargo | Upgrade | Underweight | |
2021-05-14 | Raymond James | Upgrade | Outperform | |
2021-02-08 | Wells Fargo | Downgrade | Overweight | Underweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-06-13 | ATHYRIUM OPPORTUNITIES FUND A, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2021-06-13 | BIGALKE JOHN T | Director | 47.52K | Stock Award(Grant) |
2022-04-14 | D'ESPARBES ERIC | Chief Financial Officer | 423.17K | Stock Award(Grant) |
2021-11-02 | HOWE JILL ANN | Director | 76.75K | Stock Award(Grant) |
2021-06-13 | KOTZIN BRIAN L | Director | 47.52K | Stock Award(Grant) |
2021-11-07 | MOHANTY ADITYA P | Chief Executive Officer | 1.41M | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-12-30 | Athyrium Capital Management, LP | 29.86M | 62.40M | 16.21% |
2022-03-30 | Neuberger Berman Group, LLC | 6.54M | 7.59M | 3.55% |
2022-03-30 | Vanguard Group, Inc. (The) | 5.16M | 5.98M | 2.80% |
2022-03-30 | Blackrock Inc. | 1.66M | 1.93M | 0.90% |
2022-03-30 | Geode Capital Management, LLC | 1.15M | 1.34M | 0.63% |
2022-03-30 | Susquehanna International Group, LLP | 955.32K | 1.11M | 0.52% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-12-30 | Vanguard Total Stock Market Index Fund | 3.03M | 6.32M | 1.64% |
2021-12-30 | Vanguard Extended Market Index Fund | 1.58M | 3.29M | 0.86% |
2022-02-27 | Fidelity Extended Market Index Fund | 615.33K | 830.69K | 0.33% |
2022-02-27 | Fidelity Total Market Index Fund | 210.77K | 284.53K | 0.11% |
2022-02-27 | Fidelity Series Total Market Index Fund | 121.33K | 163.79K | 0.07% |
2022-02-27 | Fidelity NASDAQ Composite Index Fund | 80.80K | 109.08K | 0.04% |
That’s the beautiful thing of selling Covered Calls, Offerings are a goldmine. Was able to buy them all out at 90% return. Now just wait for the panicking newbs to get out of the way and ride this rocket back up!
If you don’t understand how good this is then you simply don’t understand the process.
That was beautiful! Time to load up!
Loading up!!!
10 million volume already…wow
$2.65 AH
1.48 incoming..
Offering???
Market dipped hard. Recovering now
Yikes!!! This is impressive
Easy decision to add here.
Building Back Better with Biden.
Advancement of its PreecludiaTM preeclampsia rule-out test through validation and progressing physician education programs, clinical utility, health economics, and reimbursement. With topline validation anticipated in the June/July 2021 timeframe, the PreecludiaTM test is expected to target an addressable market of up to $3 billion in the U.S. alone. The PreecludiaTM test, in addition to the laboratory-developed test (LDT) immunodiagnostic, has potential as an in vitro diagnostic and point-of-care solution globally. The company is exploring partnerships for these options.
What’s up with all these buyout rumors???
39,455 shares.
$PROG buyyyy now news with AMAZON